Chairs: Beverley Bostock-Cox, Dr Chris Arden
Speakers: Jane Breen, Elizabeth Denver, Professor Terry McCormack, Beverley Bostock-Cox, Professor Mike Kirby
Professor Terry McCormack – VTE :
Venous Thrombo-Embolism Treatment guideline consultation document is not yet published. Terry McCormack, a topic-expert member of the guideline group, cannot discuss the NICE guideline. Therfore what he will do is describe how VTE is managed in Whitby Group Practice and how many hospitals currnetly manage VTE. A lot has changed in recent years.
Beverley Bostock – Respiratory:
This session gives a short, sharp, snappy overview of the latest evidence and guidance for diagnosing and managing asthma and COPD. Don’t know your restrictive spirometry from obstructive or your combinations from your dual inhalers and when to use what?
Professor Mike Kirby – Lifestyle:
Mediterranean diet, moderate alcohol intake, physical activity and not smoking are associated with lower all-cause mortality, coronary heart disease, cardiovascular disease and cancer in our patients. The combined effects of all four low risk diet and lifestyle factors significantly lower all-cause mortality rate (HR 0.4; 95%CI 0.3 to 0.5).
In summary the Mediterranean diet and healthy lifestyle, which involves moderate alcohol intake, physical activity and no smoking, is associated with a lower risk of death, so why don’t we all do it?
Elizabeth Denver – Hypertension:
The revised NICE guideline for the Diagnosis and Treatment of Hypertension in Adults was published in August 2019. The guideline supports the direction of the NHS Long Term Plan to improve outcomes in cardiovascular disease (CVD), including strokes and heart attacks, through better detection and treatment of high blood pressure.
Nurse Elizabeth Denver will explain the important changes in the new guidelines and how they were arrived at.
Jane Breen – FH:
Familial Hypercholesterolaemia (FH) is a common genetic condition associated with impaired clearance of low-density lipoprotein cholesterol (LDL-C) from the circulation. If left untreated, there is an increased risk of premature coronary heart disease (CHD), 50% of men experiencing an event by age 50 and 30% of women by age 60.
Affecting approximately 1:270, less than 7% are identified in the UK, leaving a large proportion of the population undiagnosed.
Nice provides guidance (CG71) on the identification and management of FH, supporting the use of DNA testing for the diagnosis of FH and identification of at-risk relatives through DNA cascade screening.
The Royal Brompton and Harefield NHS Foundation Trust boasts a well-established service for the identification, diagnosis and management of patients with FH. We wish to share our experience of DNA testing for genetic variants known to cause FH and the cascade screening of relatives once a molecular diagnosis is confirmed.